Jupiter Neurosciences (JUNS) vs Purple Biotech (PPBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Purple Biotech is the larger company by market cap ($1.9 million vs $1.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JUNS | PPBT |
|---|---|---|
| Share price | $1.24 | $1.53 |
| Market cap | $1.63M | $1.86M |
| 1-day change | -18.75% | -4.09% |
| Forward P/E | 20.58 | — |
| EPS (TTM) | $-22.53 | $-47.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $21.80K | — |
| Net income (latest FY) | $-8.64M | $-26.39M |
| Gross margin | 80.59% | — |
| Operating margin | -40873.19% | — |
| Net margin | -39662.77% | — |
| 52-week high | $97.73 | $8.90 |
| 52-week low | $1.20 | $0.91 |
| Distance from 52-week high | -98.74% | -82.87% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1014.75% |
| Average volume | 69.86K | 1.26M |
| Shares outstanding | 1.32M | 1.22M |
| Employees | 5 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Jupiter Neurosciences
JUNS stock →Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
JUNS vs PPBT FAQ
Which is bigger, Jupiter Neurosciences or Purple Biotech?
Purple Biotech (PPBT) is larger, with a market capitalization of $1.86M compared with $1.63M for Jupiter Neurosciences (JUNS).
Are Jupiter Neurosciences and Purple Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.